| Expression pattern: |
DS |
| Associated gene: |
TS, ABCC11, RCF1, FDZ5, MDR-1 |
| Associated microRNA: |
miR-124 |
| Biological function: |
Circ MTHFD2 enhances pemetrexed/MTA resistance and increases the survival rate of MGC-803/MTA gastric cancer cells. |
| Molecular mechanism: |
Circ MTHFD2 functions through a miR-124 molecular sponge mechanism, increasing TS and ABCC11 protein expression and decreasing RCF1 protein expression, thereby enhancing MTA resistance. |
| Biological pathway or process: |
drug resistance (promotes); chemoresistance (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; Bioinformatics Analysis; Luciferase Reporter Assay; Transfection; CCK8; Western Blot |
| Clinical significance: |
Circ MTHFD2 may provide a valuable biomarker for MTA resistance and a new drug target for overcoming gastric cancer drug resistance. |
| Description: |
This study identified circ MTHFD2 as a dysregulated circRNA associated with pemetrexed/MTA resistance in gastric cancer MGC-803/MTA cells. Functionally, circ MTHFD2 promoted drug resistance and cell survival, at least partly by binding miR-124 and altering TS, ABCC11, and RCF1 protein expression. The authors propose circ MTHFD2 as a potential biomarker and therapeutic target for overcoming MTA resistance in gastric cancer. |
| Confidence score: |
0.5804 |